This report aims to provide a comprehensive presentation of the global market for Non-Muscle-Invasive Bladder Cancer Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Muscle-Invasive Bladder Cancer Treatment. This report contains market size and forecasts of Non-Muscle-Invasive Bladder Cancer Treatment in global, including the following market information:
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Non-Muscle-Invasive Bladder Cancer Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-Muscle-Invasive Bladder Cancer Treatment include Ferring Pharmaceuticals, Merck, Sesen Bio, CG Oncology, ImmunityBio, Theralase and Viventia Bio Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Muscle-Invasive Bladder Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Muscle-Invasive Bladder Cancer Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, by Type, 2022 (%)
Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Global Non-Muscle-Invasive Bladder Cancer Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Non-Muscle-Invasive Bladder Cancer Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Muscle-Invasive Bladder Cancer Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Muscle-Invasive Bladder Cancer Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Ferring Pharmaceuticals
Merck
Sesen Bio
CG Oncology
ImmunityBio
Theralase
Viventia Bio Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Muscle-Invasive Bladder Cancer Treatment, market overview.
Chapter 2: Global Non-Muscle-Invasive Bladder Cancer Treatment market size in revenue.
Chapter 3: Detailed analysis of Non-Muscle-Invasive Bladder Cancer Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Muscle-Invasive Bladder Cancer Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Muscle-Invasive Bladder Cancer Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Muscle-Invasive Bladder Cancer Treatment Overall Market Size
2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size: 2022 VS 2029
2.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market
3.2 Top Global Non-Muscle-Invasive Bladder Cancer Treatment Companies Ranked by Revenue
3.3 Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Companies
3.4 Top 3 and Top 5 Non-Muscle-Invasive Bladder Cancer Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Muscle-Invasive Bladder Cancer Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market
3.6.1 List of Global Tier 1 Non-Muscle-Invasive Bladder Cancer Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Markets, 2022 & 2029
4.1.2 Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.1.3 Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.1.4 High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.2 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
4.2.1 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2023
4.2.2 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2024-2029
4.2.3 By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
5.2.1 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2023
5.2.2 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2024-2029
5.2.3 By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2022 & 2029
6.2 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
6.2.1 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2023
6.2.2 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2024-2029
6.2.3 By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.3.2 US Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.3.3 Canada Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.3.4 Mexico Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.4.2 Germany Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.3 France Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.4 U.K. Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.5 Italy Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.6 Russia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.8 Benelux Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.5.2 China Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5.3 Japan Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5.4 South Korea Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5.6 India Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.6.2 Brazil Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.6.3 Argentina Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.7.2 Turkey Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.7.3 Israel Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.7.5 UAE Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
7 Non-Muscle-Invasive Bladder Cancer Treatment Companies Profiles
7.1 Ferring Pharmaceuticals
7.1.1 Ferring Pharmaceuticals Company Summary
7.1.2 Ferring Pharmaceuticals Business Overview
7.1.3 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.1.4 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.1.5 Ferring Pharmaceuticals Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.2.4 Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.2.5 Merck Key News & Latest Developments
7.3 Sesen Bio
7.3.1 Sesen Bio Company Summary
7.3.2 Sesen Bio Business Overview
7.3.3 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.3.4 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.3.5 Sesen Bio Key News & Latest Developments
7.4 CG Oncology
7.4.1 CG Oncology Company Summary
7.4.2 CG Oncology Business Overview
7.4.3 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.4.4 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.4.5 CG Oncology Key News & Latest Developments
7.5 ImmunityBio
7.5.1 ImmunityBio Company Summary
7.5.2 ImmunityBio Business Overview
7.5.3 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.5.4 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.5.5 ImmunityBio Key News & Latest Developments
7.6 Theralase
7.6.1 Theralase Company Summary
7.6.2 Theralase Business Overview
7.6.3 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.6.4 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.6.5 Theralase Key News & Latest Developments
7.7 Viventia Bio Inc.
7.7.1 Viventia Bio Inc. Company Summary
7.7.2 Viventia Bio Inc. Business Overview
7.7.3 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.7.4 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.7.5 Viventia Bio Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Muscle-Invasive Bladder Cancer Treatment Market Opportunities & Trends in Global Market
Table 2. Non-Muscle-Invasive Bladder Cancer Treatment Market Drivers in Global Market
Table 3. Non-Muscle-Invasive Bladder Cancer Treatment Market Restraints in Global Market
Table 4. Key Players of Non-Muscle-Invasive Bladder Cancer Treatment in Global Market
Table 5. Top Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Muscle-Invasive Bladder Cancer Treatment Product Type
Table 9. List of Global Tier 1 Non-Muscle-Invasive Bladder Cancer Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 30. Ferring Pharmaceuticals Company Summary
Table 31. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 32. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Ferring Pharmaceuticals Key News & Latest Developments
Table 34. Merck Company Summary
Table 35. Merck Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 36. Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Merck Key News & Latest Developments
Table 38. Sesen Bio Company Summary
Table 39. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 40. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Sesen Bio Key News & Latest Developments
Table 42. CG Oncology Company Summary
Table 43. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 44. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. CG Oncology Key News & Latest Developments
Table 46. ImmunityBio Company Summary
Table 47. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 48. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. ImmunityBio Key News & Latest Developments
Table 50. Theralase Company Summary
Table 51. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 52. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Theralase Key News & Latest Developments
Table 54. Viventia Bio Inc. Company Summary
Table 55. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 56. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Viventia Bio Inc. Key News & Latest Developments
List of Figures
Figure 1. Non-Muscle-Invasive Bladder Cancer Treatment Segment by Type in 2022
Figure 2. Non-Muscle-Invasive Bladder Cancer Treatment Segment by Application in 2022
Figure 3. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Muscle-Invasive Bladder Cancer Treatment Revenue in 2022
Figure 8. By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 9. By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 10. By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 12. By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 14. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 15. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 16. US Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 20. Germany Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 21. France Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 28. China Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. India Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 34. Brazil Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 37. Turkey Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
